Zimmer Biomet Stock: Analyst Estimates & Ratings

Core Viewpoint - Zimmer Biomet Holdings, Inc. has significantly underperformed the broader market, with stock prices declining sharply over the past year, despite some positive sales growth in its recent quarterly results [2][4]. Company Overview - Zimmer Biomet, based in Warsaw, Indiana, operates as a medical technology company focused on designing, manufacturing, and marketing orthopedic reconstructive products. The company has a market capitalization of $17.6 billion and serves various healthcare professionals and institutions [1]. Stock Performance - ZBH stock has dropped 16.2% year-to-date and 19.2% over the past 52 weeks, contrasting with the S&P 500 Index's returns of 16.4% in 2025 and 14.1% over the past year [2]. - The company has also underperformed compared to the US Medical Devices Ishares ETF, which gained 7.2% in 2025 and 3.5% over the past 52 weeks [3]. Recent Financial Results - Following the release of mixed Q3 results on November 5, ZBH's stock fell 15.2% in a single trading session. The company reported a 5% increase in organic sales on a constant currency basis and a 3.6% rise in overall sales due to acquisition-related growth, with net sales reaching $2 billion, a 9.7% year-over-year increase [4]. - Despite a positive currency translation impact of 1.1%, sales fell short of market expectations by 42 basis points. However, adjusted EPS grew 9.2% year-over-year to $1.90, exceeding consensus estimates by 1.1% [4]. Future Earnings Expectations - For the full fiscal year 2025, analysts project an adjusted EPS of $8.17, reflecting a 2.1% year-over-year increase. The company has a strong earnings surprise history, having surpassed bottom-line estimates in the last four quarters [5]. - Among 27 analysts covering ZBH, the consensus rating is a "Moderate Buy," consisting of seven "Strong Buys," two "Moderate Buys," 16 "Holds," and two "Strong Sells" [5]. Analyst Ratings and Price Targets - Canaccord Genuity analyst Caitlin Roberts maintained a "Hold" rating on ZBH but reduced the price target from $101 to $93. The mean price target of $103.48 indicates a 16.9% premium to current price levels, while the highest target of $135 suggests a potential upside of 52.5% [7].